USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
Borrowers Under 30 Show Highest Loan Default Rates On Unsecured & Vehicle Loans: Crif Report
HDB Financial Services Q3 Profit Jumps 36% To ₹644 Crore, AUM Crosses ₹1.14 Lakh Crore
BMC Elections 2026: Maharashtra Minister Ashish Shelar, Actor Akshay Kumar Among Early Voters Cast Ballots As Polling Begins In Mumbai
US ICE Shooting: 2 Injured As Federal Agents Open Fire After Being Attacked With Shovel; 2nd Such Incident In Minneapolis This Month | VIDEO
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
